This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CorMedix Reports Second Quarter 2011 Results

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced its results for the second quarter ended June 30, 2011.

Second Quarter 2011 Highlights:

  • Submitted Design Dossier for (CRMD003) Neutrolin ® as part of the European CE Mark Approval Process
  • Special Protocol Assessment (“SPA”) Agreement with FDA for Phase III Trial in Prevention of Contrast Induced Acute Kidney Injury (“CI-AKI”) with (CRMD001), A Proprietary Formulation of Deferiprone
  • Successfully Completed Patient Recruitment in Phase II CI-AKI with (CRMD001), A Proprietary Formulation of Deferiprone

Planned Second Half 2011 Milestones:

  • Announce data from Phase II CI-AKI Study for (CRMD001), A Proprietary Formulation of Deferiprone
  • Start Pivotal Phase III Clinical Study for (CRMD003) Neutrolin ® Pending FDA Approval

Financial Results for the Second Quarter 2011

The net loss for the three months ended June 30, 2011 was $2.5 million, or $0.22 per diluted share, compared to a net loss of $1.2 million, or $0.10 per diluted share, for the second quarter 2010. The increase in the net loss was attributable to increased research and development (“R&D”) of $0.6 million and general and administrative (“G&A”) expenses of $0.3 million during the second quarter of 2011 compared to the second quarter of 2010 as a result of the Company completing patient recruitment in its Phase II study of CRMD-001, increased development and regulatory costs for CRMD-003, as well as increased stock-based compensation costs and costs of operating as a publicly-traded company following our IPO in March 2010, respectively.

The net loss for the six months ended June 30, 2011 was $4.5 million, or $0.39 per diluted share, compared to a net loss of $7.6 million, or $1.14 per diluted share, for the six months ended June 30, 2010. The decrease in net loss was attributable to a decrease of interest expense of $3.1 million comprised of amortization and write-off of deferred financing costs and debt discounts which was related to the completion of the Company’s IPO occurring in the first quarter 2010 with no related charges during the first half of 2011.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs